Annual Cash & Cash Equivalents
$28.68 M
+$13.31 M+86.65%
31 December 2023
Summary:
Heron Therapeutics annual cash & cash equivalents is currently $28.68 million, with the most recent change of +$13.31 million (+86.65%) on 31 December 2023. During the last 3 years, it has fallen by -$76.46 million (-72.72%). HRTX annual cash & cash equivalents is now -80.17% below its all-time high of $144.58 million, reached on 31 December 2017.HRTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$25.74 M
+$7.36 M+40.00%
30 September 2024
Summary:
Heron Therapeutics quarterly cash and cash equivalents is currently $25.74 million, with the most recent change of +$7.36 million (+40.00%) on 30 September 2024. Over the past year, it has dropped by -$9.12 million (-26.16%). HRTX quarterly cash and cash equivalents is now -90.06% below its all-time high of $258.93 million, reached on 30 June 2018.HRTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HRTX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +86.7% | -26.2% |
| 3 y3 years | -72.7% | -83.9% |
| 5 y5 years | -9.9% | -57.2% |
HRTX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -72.7% | +86.7% | -83.9% | +91.2% |
| 5 y | 5 years | -72.7% | +86.7% | -86.5% | +91.2% |
| alltime | all time | -80.2% | >+9999.0% | -90.1% | >+9999.0% |
Heron Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $25.74 M(+40.0%) |
| June 2024 | - | $18.39 M(-10.1%) |
| Mar 2024 | - | $20.45 M(-28.7%) |
| Dec 2023 | $28.68 M(+86.7%) | $28.68 M(-17.7%) |
| Sept 2023 | - | $34.86 M(+158.9%) |
| June 2023 | - | $13.46 M(-50.3%) |
| Mar 2023 | - | $27.09 M(+76.3%) |
| Dec 2022 | $15.36 M(-83.0%) | $15.36 M(-69.5%) |
| Sept 2022 | - | $50.44 M(+3.8%) |
| June 2022 | - | $48.61 M(-14.6%) |
| Mar 2022 | - | $56.91 M(-37.1%) |
| Dec 2021 | $90.54 M(-13.9%) | $90.54 M(-43.3%) |
| Sept 2021 | - | $159.57 M(-16.5%) |
| June 2021 | - | $191.17 M(+220.0%) |
| Mar 2021 | - | $59.74 M(-43.2%) |
| Dec 2020 | $105.14 M(+46.2%) | $105.14 M(+10.5%) |
| Sept 2020 | - | $95.14 M(+17.9%) |
| June 2020 | - | $80.73 M(-21.8%) |
| Mar 2020 | - | $103.28 M(+43.7%) |
| Dec 2019 | $71.90 M(+125.8%) | $71.90 M(+19.6%) |
| Sept 2019 | - | $60.11 M(+13.3%) |
| June 2019 | - | $53.04 M(+126.1%) |
| Mar 2019 | - | $23.46 M(-26.3%) |
| Dec 2018 | $31.84 M(-78.0%) | $31.84 M(-41.0%) |
| Sept 2018 | - | $53.93 M(-79.2%) |
| June 2018 | - | $258.93 M(+456.0%) |
| Mar 2018 | - | $46.58 M(-67.8%) |
| Dec 2017 | $144.58 M(+977.9%) | $144.58 M(+120.7%) |
| Sept 2017 | - | $65.52 M(+116.4%) |
| June 2017 | - | $30.28 M(-63.7%) |
| Mar 2017 | - | $83.51 M(+522.6%) |
| Dec 2016 | $13.41 M(-82.2%) | $13.41 M(-70.6%) |
| Sept 2016 | - | $45.64 M(-26.3%) |
| June 2016 | - | $61.94 M(-8.9%) |
| Mar 2016 | - | $68.02 M(-9.5%) |
| Dec 2015 | $75.18 M(+3.4%) | $75.18 M(-50.9%) |
| Sept 2015 | - | $152.99 M(-10.8%) |
| June 2015 | - | $171.53 M(+208.7%) |
| Mar 2015 | - | $55.56 M(-23.6%) |
| Dec 2014 | $72.67 M(+0.5%) | $72.67 M(-15.7%) |
| Sept 2014 | - | $86.21 M(-17.9%) |
| June 2014 | - | $105.01 M(+82.7%) |
| Mar 2014 | - | $57.48 M(-20.5%) |
| Dec 2013 | $72.29 M(+35.1%) | $72.29 M(+219.9%) |
| Sept 2013 | - | $22.60 M(-35.2%) |
| June 2013 | - | $34.85 M(-23.8%) |
| Mar 2013 | - | $45.72 M(-14.5%) |
| Dec 2012 | $53.51 M(+197.7%) | $53.51 M(-10.9%) |
| Sept 2012 | - | $60.05 M(+382.6%) |
| June 2012 | - | $12.44 M(-7.5%) |
| Mar 2012 | - | $13.44 M(-25.2%) |
| Dec 2011 | $17.97 M(+752.3%) | $17.97 M(-14.5%) |
| Sept 2011 | - | $21.02 M(-1.5%) |
| June 2011 | - | $21.33 M(+1866.0%) |
| Mar 2011 | - | $1.08 M(-48.6%) |
| Dec 2010 | $2.11 M(-72.2%) | $2.11 M(-30.0%) |
| Sept 2010 | - | $3.02 M(-47.4%) |
| June 2010 | - | $5.74 M(-24.1%) |
| Mar 2010 | - | $7.56 M(-0.4%) |
| Dec 2009 | $7.59 M(-23.8%) | $7.59 M(+383.9%) |
| Sept 2009 | - | $1.57 M(-56.5%) |
| June 2009 | - | $3.61 M(-49.2%) |
| Mar 2009 | - | $7.11 M(-28.7%) |
| Dec 2008 | $9.97 M(-70.3%) | $9.97 M(-36.4%) |
| Sept 2008 | - | $15.68 M(-23.0%) |
| June 2008 | - | $20.36 M(-23.2%) |
| Mar 2008 | - | $26.50 M(-20.9%) |
| Dec 2007 | $33.51 M(+1336.3%) | $33.51 M(-11.5%) |
| Sept 2007 | - | $37.87 M(-7.0%) |
| June 2007 | - | $40.71 M(+3950.7%) |
| Mar 2007 | - | $1.00 M(-56.9%) |
| Dec 2006 | $2.33 M | $2.33 M(-38.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2006 | - | $3.77 M(-36.6%) |
| June 2006 | - | $5.94 M(-45.8%) |
| Mar 2006 | - | $10.97 M(+1288.6%) |
| Dec 2005 | $790.00 K(-74.6%) | $790.00 K(-65.4%) |
| Sept 2005 | - | $2.28 M(+15.7%) |
| June 2005 | - | $1.97 M(+457.1%) |
| Mar 2005 | - | $354.00 K(-88.6%) |
| Dec 2004 | $3.11 M(+3106.2%) | $3.11 M(+362.1%) |
| Sept 2004 | - | $673.00 K(-88.4%) |
| June 2004 | - | $5.81 M(+142.2%) |
| Mar 2004 | - | $2.40 M(+2374.2%) |
| Dec 2003 | $97.00 K(-97.0%) | $97.00 K(-93.4%) |
| Sept 2003 | - | $1.47 M(+18.3%) |
| June 2003 | - | $1.25 M(-65.7%) |
| Mar 2003 | - | $3.63 M(+10.7%) |
| Dec 2002 | $3.28 M(-9.3%) | $3.28 M(-49.9%) |
| Sept 2002 | - | $6.56 M(+255.5%) |
| June 2002 | - | $1.84 M(-61.6%) |
| Mar 2002 | - | $4.80 M(+32.7%) |
| Dec 2001 | $3.62 M(-44.3%) | $3.62 M(+37.7%) |
| Sept 2001 | - | $2.63 M(-36.8%) |
| June 2001 | - | $4.16 M(-13.4%) |
| Mar 2001 | - | $4.80 M(-26.1%) |
| Dec 2000 | $6.49 M(+75.2%) | $6.49 M(-34.4%) |
| Sept 2000 | - | $9.90 M(+270.8%) |
| June 2000 | - | $2.67 M(-24.5%) |
| Mar 2000 | - | $3.54 M(-4.5%) |
| Dec 1999 | $3.71 M(-9.6%) | $3.71 M(+5.9%) |
| Sept 1999 | - | $3.50 M(0.0%) |
| June 1999 | - | $3.50 M(-35.2%) |
| Mar 1999 | - | $5.40 M(+31.7%) |
| Dec 1998 | $4.10 M(-52.9%) | $4.10 M(+20.6%) |
| Sept 1998 | - | $3.40 M(-34.6%) |
| June 1998 | - | $5.20 M(-18.8%) |
| Mar 1998 | - | $6.40 M(-26.4%) |
| Dec 1997 | $8.70 M(+61.1%) | $8.70 M(+2.4%) |
| Sept 1997 | - | $8.50 M(+14.9%) |
| June 1997 | - | $7.40 M(+37.0%) |
| Mar 1997 | - | $5.40 M(0.0%) |
| Dec 1996 | $5.40 M(+3.8%) | $5.40 M(-26.0%) |
| Sept 1996 | - | $7.30 M(-2.7%) |
| June 1996 | - | $7.50 M(+36.4%) |
| Mar 1996 | - | $5.50 M(+5.8%) |
| Dec 1995 | $5.20 M(+92.6%) | $5.20 M(-14.8%) |
| Sept 1995 | - | $6.10 M(+177.3%) |
| June 1995 | - | $2.20 M(-47.6%) |
| Mar 1995 | - | $4.20 M(+55.6%) |
| Dec 1994 | $2.70 M(+50.0%) | $2.70 M(-55.0%) |
| Sept 1994 | - | $6.00 M(-17.8%) |
| June 1994 | - | $7.30 M(+160.7%) |
| Mar 1994 | - | $2.80 M(+55.6%) |
| Dec 1993 | $1.80 M(-33.3%) | $1.80 M(+63.6%) |
| Sept 1993 | - | $1.10 M(+175.0%) |
| June 1993 | - | $400.00 K(-81.0%) |
| Mar 1993 | - | $2.10 M(-22.2%) |
| Dec 1992 | $2.70 M(+68.8%) | $2.70 M(-61.4%) |
| Sept 1992 | - | $7.00 M(+59.1%) |
| June 1992 | - | $4.40 M(-8.3%) |
| Mar 1992 | - | $4.80 M(+200.0%) |
| Dec 1991 | $1.60 M(-5.9%) | $1.60 M(+14.3%) |
| Sept 1991 | - | $1.40 M(-41.7%) |
| June 1991 | - | $2.40 M(0.0%) |
| Mar 1991 | - | $2.40 M(+41.2%) |
| Dec 1990 | $1.70 M(-34.6%) | $1.70 M(-58.5%) |
| Sept 1990 | - | $4.10 M(+24.2%) |
| June 1990 | - | $3.30 M(+6.5%) |
| Mar 1990 | - | $3.10 M(+19.2%) |
| Dec 1989 | $2.60 M(-77.2%) | $2.60 M(-70.1%) |
| Sept 1989 | - | $8.70 M(-8.4%) |
| June 1989 | - | $9.50 M(-16.7%) |
| Dec 1988 | $11.40 M(-28.3%) | $11.40 M(-28.3%) |
| Dec 1987 | $15.90 M | $15.90 M |
FAQ
- What is Heron Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Heron Therapeutics?
- What is Heron Therapeutics annual cash & cash equivalents year-on-year change?
- What is Heron Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Heron Therapeutics?
- What is Heron Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Heron Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of HRTX is $28.68 M
What is the all time high annual cash & cash equivalents for Heron Therapeutics?
Heron Therapeutics all-time high annual cash & cash equivalents is $144.58 M
What is Heron Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, HRTX annual cash & cash equivalents has changed by +$13.31 M (+86.65%)
What is Heron Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of HRTX is $25.74 M
What is the all time high quarterly cash and cash equivalents for Heron Therapeutics?
Heron Therapeutics all-time high quarterly cash and cash equivalents is $258.93 M
What is Heron Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, HRTX quarterly cash and cash equivalents has changed by -$9.12 M (-26.16%)